Skip to content
Yog Pharma
CardiovascularHMG-CoA reductase inhibitor (statin)

Atorvastatin Calcium is an HMG-CoA reductase inhibitor (statin) indicated for primary hyperlipidemia, mixed dyslipidemia and reduction of cardiovascular risk. We supply it to US manufacturers of tablets.

CAS134523-03-81155.3 g/molC66H68CaF2N4O10
2D structure of Atorvastatin Calcium, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 60822) and FDA’s substance registry

CAS number

134523-03-8

Molecular formula

C66H68CaF2N4O10

Molecular weight

1155.3g/mol

FDA UNII

IUPAC name

calcium bis((3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate)

InChIKey

FQCKMBLVYCEXJB-MNSAWQCASA-L

Appearance
White to off-white powder.
Solubility
Insoluble in aqueous solutions of pH 4 and below, and very slightly soluble in water. Freely soluble in methanol and slightly soluble in ethanol.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Supplied as the crystalline trihydrate or as amorphous material. The two differ in solubility and stability and are covered by separate DMFs, so state the form you developed with.

On the US market

Reference product
LipitorNDA 020702
Approved ANDAs
24 with a marketed product
Approved forms and strengths
  • Tablet 10 mg, 20 mg, 40 mg, 80 mg
  • Oral suspension 20 mg/5 mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com